JP2023513298A5 - - Google Patents

Info

Publication number
JP2023513298A5
JP2023513298A5 JP2022548573A JP2022548573A JP2023513298A5 JP 2023513298 A5 JP2023513298 A5 JP 2023513298A5 JP 2022548573 A JP2022548573 A JP 2022548573A JP 2022548573 A JP2022548573 A JP 2022548573A JP 2023513298 A5 JP2023513298 A5 JP 2023513298A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
approximately
dose
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022548573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513298A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/053384 external-priority patent/WO2021160763A1/en
Publication of JP2023513298A publication Critical patent/JP2023513298A/ja
Publication of JP2023513298A5 publication Critical patent/JP2023513298A5/ja
Withdrawn legal-status Critical Current

Links

JP2022548573A 2020-02-12 2021-02-11 尿路上皮癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤及び抗ｐｄ１剤 Withdrawn JP2023513298A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202062975526P 2020-02-12 2020-02-12
US62/975,526 2020-02-12
US202063025817P 2020-05-15 2020-05-15
US63/025,817 2020-05-15
US202063055187P 2020-07-22 2020-07-22
US63/055,187 2020-07-22
US202063078205P 2020-09-14 2020-09-14
US63/078,205 2020-09-14
US202063078736P 2020-09-15 2020-09-15
US63/078,736 2020-09-15
US202063083316P 2020-09-25 2020-09-25
US63/083,316 2020-09-25
PCT/EP2021/053384 WO2021160763A1 (en) 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma

Publications (2)

Publication Number Publication Date
JP2023513298A JP2023513298A (ja) 2023-03-30
JP2023513298A5 true JP2023513298A5 (https=) 2024-02-21

Family

ID=74666674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548573A Withdrawn JP2023513298A (ja) 2020-02-12 2021-02-11 尿路上皮癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤及び抗ｐｄ１剤

Country Status (15)

Country Link
US (1) US20230135136A1 (https=)
EP (1) EP4103184A1 (https=)
JP (1) JP2023513298A (https=)
KR (1) KR20220140777A (https=)
CN (1) CN115087446A (https=)
AU (1) AU2021219948A1 (https=)
BR (1) BR112022015825A2 (https=)
CA (1) CA3163407A1 (https=)
IL (1) IL295515A (https=)
JO (1) JOP20220181A1 (https=)
MX (1) MX2022009904A (https=)
PH (1) PH12022552091A1 (https=)
TW (1) TWI900527B (https=)
UY (1) UY39080A (https=)
WO (1) WO2021160763A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925954A (zh) * 2022-12-28 2023-04-07 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib
WO2025046898A1 (ja) * 2023-08-31 2025-03-06 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬を含む癌治療法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
KR102662228B1 (ko) * 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
MX2018006181A (es) * 2015-11-23 2018-09-24 Five Prime Therapeutics Inc Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
TWI798199B (zh) * 2017-02-06 2023-04-11 比利時商健生藥品公司 癌症治療
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Similar Documents

Publication Publication Date Title
KR20240021237A (ko) 두경부암 치료를 위한 egfr 저해제
JP2023513298A5 (https=)
JP2022527482A5 (https=)
US20230181565A1 (en) Crenolanib combination therapy
WO2017200016A1 (ja) Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬
JP2020505425A5 (https=)
CN113082035A (zh) Ly3009120在制备治疗骨髓增殖性肿瘤的药物中的应用
TW201141473A (en) Combination therapy for small cell lung cancer
Arceci et al. A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis
AU2025223785A1 (en) 1-(4-{[4-(Dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
KR20150090091A (ko) 볼라세르티브와의 병용 요법
JP7278405B2 (ja) 小細胞肺がんの治療におけるキアウラニブの使用
US20130316998A1 (en) Method for treating pancreatic cancer
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
Goyal et al. Role of Curcumin in reducing toxicity and adverse effects in locally advanced and metastatic breast cancer patients
JP2023542296A5 (https=)
US20220348662A1 (en) Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
CN114984015A (zh) 治疗增殖性疾病的联用药物组合物
JP2022527189A5 (https=)
JP5865896B2 (ja) 胃癌を処置する方法
RU2827402C2 (ru) Фармацевтическая композиция, содержащая пиридинаминное соединение, и ее применение при ros1-положительном немелкоклеточном раке легкого
Xu et al. Severe rhabdomyolysis associated with etoposide-nedaplatin chemotherapy in a patient with small cell lung cancer: case report and review of literature
WO2024121861A1 (en) Egfr inhibitor for the treatment of head and neck cancer
CN112516140A (zh) 奥美拉唑减轻酪氨酸激酶抑制剂毒副作用的用途
WO2024231875A1 (en) Hpk1 inhibitor for use in the treatment of cancer